SEC Company Response from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF) — May 8, 2020
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: May 8, 2020 · CIK: 0001601936 · Accession: 0001213900-20-011343
AI Filing Summary & Sentiment
File numbers found in text: 333-237907
Letter
Re: Auris Medical Holding Ltd.
May 8, 2020
Registration Statement on Form F-1
Registration No. 333-237907
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:00 a.m. Eastern Standard Time on May 11, 2020 or as soon thereafter as is practicable.
Sincerely,
Auris Medical Holding Ltd.
Show Raw Text
CORRESP
1
filename1.htm
May 8, 2020
Re:
Auris Medical Holding Ltd.
Registration Statement on Form F-1
Registration No. 333-237907
Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective
date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:00 a.m. Eastern
Standard Time on May 11, 2020 or as soon thereafter as is practicable.
Sincerely,
Auris Medical Holding Ltd.
By:
/s/
Thomas Meyer
Name:
Thomas
Meyer
Title:
Chief
Executive Officer
Via
EDGAR